Hims & Hers Health, Inc. (HIMS) appears an attractive pick given a noticeable improvement in the company's earnings outlook.

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

Shares of Hims & Hers have crushed the market over the last year. When it comes to stocks that continue to beat the market, my guess is that your mind goes straight to companies leading the charge in ...

Hims & Hers (NYSE: HIMS) stock, a prominent player in the booming telehealth sector, has undeniably captured significant investor attention recently. Perhaps you, like many others, have been caught up ...

Hims & Hers Health, Inc. (HIMS) closed at $55.25 in the latest trading session, marking a -2.83% move from the prior day. This change lagged the S&P 500's 0.55% gain on the day. At the same time, the ...

HIMS posted stellar Q1 FY 2025; growth fueled by ~2.4M subscribers and $84 average monthly revenue per user. Click here to ...

Hims & Hers Health agreed to acquire Zava, a digital health platform in Europe. The telehealth-consultation platform said its acquisition will expand its footprint into the United Kingdom and ...

Tuesday, online health and wellness company Hims & Hers announced its intent to acquire European digital healthcare provider ...